Acorda Therapeutics Cdt Stock
Your prediction
Pros and Cons of Acorda Therapeutics Cdt in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
S********** s********
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Acorda Therapeutics Cdt vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Acorda Therapeutics Cdt | - | - | - | - | - | - | - |
| Heron Therapeutics Inc. | -0.770% | 1.801% | -17.992% | -58.805% | -36.580% | -66.357% | -95.128% |
| Evolus Inc | -0.560% | 2.890% | -21.586% | -60.663% | -34.679% | -51.892% | -68.214% |
| Sangamo Therapeutics Inc. | -1.650% | -15.717% | -38.107% | -65.898% | -36.993% | -85.186% | -97.618% |
Comments
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for ACOR provided by MarketBeat
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for ACOR provided by MarketBeat
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for ACOR provided by MarketBeat